Steven Pfanstiel ’95 was recently hired as the Chief Financial Officer for Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
“Marinus is committed to making a significant difference in the lives of people touched by rare pediatric and refractory epilepsy,” Pfanstiel said in a news release. “The science is strong, and I am pleased to bring a strong financial discipline and foundation to support the company in its continued development activities and as it plans for commercialization of ganaxolone.”
Pfanstiel has a long track record in life sciences and pharmaceuticals, supporting the financial side of R&D, supply chain, and global commercialization organizations.
Before joining Marinus, Pfanstiel worked for 16 years in various divisions and operating companies of Johnson & Johnson.
He was most recently the Vice President of Finance for LifeScan of Malvern, a world leader in blood glucose monitoring known for its OneTouch brand products for managing diabetes, according to a news release. At LifeScan, he was responsible for a finance team of over 40 and drove significant cost savings while optimizing investment in sales and marketing.
Dr. Scott Braunstein, Chief Executive Officer of Marinus Pharmaceuticals, said Pfanstiel is a “stellar leader” who will be instrumental in positioning the company for its next phase of growth.
“(Pfanstiel) brings skills and seasoned expertise that will prove invaluable as we build our organization and prepare for potential commercial launch,” Braunstein said in a news release.
Pfanstiel majored in physics at Wabash College and was a member of Delta Tau Delta. He holds a M.S. in environmental systems engineering from Clemson University and an M.B.A. in finance from the Indiana University Kelley School of Business in Indianapolis.